RedHill Biopharma (RDHL) announced that the Company received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market dated April 15, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550. The Rule requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. However, based on the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed on April 10, 2025, the Company reported a stockholders’ deficit of $4,683,000, and does not meet the alternatives of market value of listed securities or net income from continuing operations, and is thus non-compliant with the Rule. The Company is looking into various options available to regain compliance and maintain its continued listing on the Nasdaq Capital Market.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma’s Opaganib Shows Promise in Obesity and Diabetes Market Disruption
- RedHill Biopharma announces publication in journal on Opaganib
- RedHill Biopharma Reports 2024 Financial Results and Strategic Advances
- RedHill Biopharma Announces Board Resignation of Eric Swenden
- RedHill Biopharma Announces Agenda for 2025 Annual General Meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue